Latest revenue
$116.3M
as of 2026-03-31
Latest net income
$1.4M
as of 2026-03-31
Net margin
1.2%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think AORT is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $977.7M
- Enterprise value
- $1.14B
- P/E (trailing)
- 100.1×
- Forward P/E
- —
- P/B
- 2.17×
- Dividend yield
- 0.0%
- 52-wk high
- $48.25
- 52-wk low
- $19.16
- Beta
- —
- Shares out
- 48.5M
5-year trend
What this company does
Item 1. Business. Overview Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products (“On-X” products), surgical sealants, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Aortic arch stent grafts include our E-vita® Open NEO, E-vita Open Plus, Arcevo™ LSA Hybrid Stent…
AI summary unavailable — showing raw filing excerpt
Generated from AORT's filing dated 2026-02-18
Key risks
Item 1A. Risk Factors. Risks Relating to Our Business Our business involves a variety of risks and uncertainties, known and unknown, including, among others, the risks discussed below. These risks should be carefully considered together with the other information provided in this Annual Report on Form 10-K and in our other filings with the US Securities and Exchange Commission (the “SEC”). Our failure to adequately anticipate or address these risks and uncertainties may have a material, adverse impact on our business, reputation, revenues, financial condition, profitability, and cash flows. Additional risks and uncertainties not presently known or knowable to us, or that we currently…
AI summary unavailable — showing raw filing excerpt
Generated from AORT's filing dated 2026-02-18
Profitability
Gross margin
64.4%
0.6%Operating margin
7.6%
23.6%Net margin
2.2%
164.4%Return on equity
2.2%
145.1%Return on assets
1.1%
165.2%Leverage
Debt / equity
0.97×
47.6%Long-term debt / equity
0.48×
57.8%Debt / assets
49.3%
24.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $116.3M | +17.5% | $1.4M | +380.6% | 1.2% |
Q4 2025 2025-12-31 | $116.0M | +19.2% | $2.9M | +117.8% | 2.5% |
Q3 2025 2025-09-30 | $113.4M | +18.4% | $6.5M | +384.2% | 5.7% |
Q2 2025 2025-06-30 | $113.0M | +15.3% | $840.0K | +139.6% | 0.7% |
Q1 2025 2025-03-31 | $99.0M | +1.6% | $-505.0K | -106.7% | -0.5% |
Q4 2024 2024-12-31 | $97.3M | — | $-16.5M | — | -16.9% |
Q3 2024 2024-09-30 | $95.8M | +9.0% | $-2.3M | +76.7% | -2.4% |
Q2 2024 2024-06-30 | $98.0M | +9.8% | $-2.1M | +37.3% | -2.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on AORT — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$22.0M
Net activity
−$22.0M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AORT
Institutional value
$668.2M
Total shares held
19.2M
Distinct holders
140
-102 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.5M | $237.1M | +106.7K (+1.7%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $71.5M | — | New |
| 3 | Conestoga Capital Advisors, LLC | 1.2M | $43.0M | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.0M | $38.0M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 1.0M | $37.6M | +46.7K (+4.8%) | Added |
| 6 | YARGER WEALTH STRATEGIES, LLC | 634.2K | $23.2M | — | New |
| 7 | ROYCE & ASSOCIATES LP | 425.3K | $15.6M | -7.5K (-1.7%) | Trimmed |
| 8 | Invesco Ltd. | 375.0K | $13.7M | -726.2K (-65.9%) | Trimmed |
| 9 | PEREGRINE CAPITAL MANAGEMENT LLC | 342.8K | $12.6M | +47.1K (+15.9%) | Added |
| 10 | First Eagle Investment Management, LLC | 311.6K | $11.4M | +4.7K (+1.5%) | Added |
| 11 | KENNEDY CAPITAL MANAGEMENT LLC | 299.3K | $11.0M | -139.4K (-31.8%) | Trimmed |
| 12 | VANGUARD FIDUCIARY TRUST CO | 292.3K | $10.7M | — | New |
| 13 | PRINCIPAL FINANCIAL GROUP INC | 261.4K | $9.6M | +20.9K (+8.7%) | Added |
| 14 | UBS Group AG | 256.9K | $9.4M | -22.8K (-8.1%) | Trimmed |
| 15 | Bank of New York Mellon Corp | 242.5K | $8.9M | -4.2K (-1.7%) | Trimmed |
| 16 | Summit Creek Advisors LLC | 189.1K | $6.9M | +48.3K (+34.3%) | Added |
| 17 | Legal & General Group Plc | 185.1K | $6.8M | -5.7K (-3.0%) | Trimmed |
| 18 | SEI INVESTMENTS CO | 168.0K | $6.2M | +53.7K (+47.0%) | Added |
| 19 | WASATCH ADVISORS LP | 156.4K | $5.7M | -48.1K (-23.5%) | Trimmed |
| 20 | FIRST TRUST ADVISORS LP | 151.4K | $5.5M | +14.9K (+10.9%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AORT's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.